Comment les stratégies chirurgicales sont modifiées par les nouveaux traitements adjuvants: en pathologie colorectale

The management of gastric cancer has dramatically changed in the last 3 decades as a parallel to advancements in the standardisation of radical surgery, the arrival and intensification of neoadjuvant chemotherapy, the implementation of prehabilitation. Nowadays, the debate is focused on the personalized approach depending on biomarkers such as MMR status, CPS/TAP score, Her2 and Claudine 18.2 status. However the susceptibility of MSI-high gastric cancers to immunotherapy is lower than some other digestive cancers. Concerning surgery, the minimally invasive surgery as well as intraperitoneal prophylactic treatment should be discussed. A preoperative prehabilitation as well as ERAS strategies can further improve surgical results.